Table 1.

Demographics and concurrent medical therapies of patients in the case-control group (N=20) and Dornase alfa treatment group (N=10).

Demographics	Case-Control (N=20)	Dornase alfa (N=10)	P-Value
Age (years)*	60 (24-84)	63 (47-79)	0.65
Gender**
Male	13 (65%)	6 (60%)	0.8
Female	7 (35%)	4 (40%)	0.8
Ethnicity**
White, non-hispanic	16 (80%)	8 (80%)	>0.999
African American	1 (5%)	0 (0%)	0.49
Hispanic/Latino	3 (15%)	2 (20%)	0.74
Co-Morbidities**
Diabetes	11 (55%)	7 (70%)	0.45
Hypertension	14 (70%)	9 (90%)	0.24
Coronary artery	7 (35%)	5 (50%)	0.45
Disease
Chronic lung disease	7 (35%)	3 (30%)	0.79
(COPD, asthma, ILD)
Obesity	17 (85%)	8 (80%)	0.79
Therapies Received**
Remdesivir	20 (100%)	9 (90%)	0.16
Corticosteroids	20 (100%)	9 (90%)	0.16
Antibiotics	19 (95%)	10 (100%)	0.49
Convalescent Plasma	11 (55%)	9 (90%)	0.06
Anticoagulation	10 (50%)	4 (40%)	0.62
Paralytics	19 (95%)	8 (80%)	0.21
Prone positioning	16 (80%)	8 (80%)	>0.999

*(mean, min to max) **(total and % of patient population). COPD, Chronic Obstructive Pulmonary Disease; ILD, Interstitial Lung Disease.